Eminyakeni yamuva nje, umphumela we-immune checkpoint inhibitors ekwelapheni i-Hodgkin's lymphoma (HL) uyamangalisa, kodwa lesi sifo sisadinga ukunqotshwa ngokucophelela. USihlalo we-Mayo Clinic's Lymphoma Group u-Ansell uthe.
Abacwaningi eNyuvesi yaseCalifornia, eSan Francisco naseSt. Jude Children's Research Hospital eTennessee baxazulule izimfihlakalo zezokwelapha emashumini eminyaka adlule, futhi bathole ukuguqulwa kofuzo okubili okungase kubangele ukufa.
I-FDA inikeze i-quizartinib yomuthi wayo ophumelelayo ukwelashwa okuphumelelayo. I-Quizartinib iyi-FLT3 inhibitor ephenywayo yokwelashwa kweziguli ezikhulile ezine-FLT3-ITD acute myeloi ebuyele emuva / ephikisayo.
I-US Food and Drug Administration igunyaze i-Venetoclax (Venclexta) ehlanganiswe ne-rituximab (VenR) yokwelapha iziguli ezine-lymphocytic leukemia (CLL) engapheli ngokusekelwe kudatha encane ye-residual disease (MRD) yesigaba.
Ngokocwaningo lwezokwelapha olugxile ezindaweni eziningi oluholwa abacwaningi e-Stanford University School of Medicine, uhlobo olusha lwe-immunotherapy lubonakala luphephile ezigulini ezinomdlavuza wegazi olubizwa nge-non-Hodgkin's lymphoma.The therapy com.
Ngokwemiphumela yesigaba sesibili socwaningo, inhlanganisela ye-standard-care chemotherapy drug azacitidine kanye ne-immune checkpoint inhibitor nivolumab (nivolumab) ibonise ukuthi izinga lokuphendula nokuphindaphinda.
On November 28, FDA approved the first rituximab (Rituxan, rituximab) biosimilar, Truxima (rituximab-abbs, Celltrion Inc.) for non-Hodgkin's lymphoma (NHL). Rituximab is a monoclonal antibody against CD20. It is widely used..
I-US FDA igunyaze i-gilteritinib (i-Xospata) yokwelashwa kweziguli ezikhulile ezine-FLT3 mutation-positive relapse noma i-refractory acute myeloid leukemia ( AML ). Lapho isetshenziswa ne-gil..
Imiphumela yocwaningo lomtholampilo lwesigaba sesi-III esinezikhungo eziningi ibonise ukuthi uma iziguli esezikhulile ezine-lymphocytic leukemia (CLL) zelashwa ngomuthi omusha ohlosiwe i-ibrutinib uma kuqhathaniswa ne-commo yangaphambili.
I-Venetoclax (i-Venclexta) kanye ne-rituximab (i-Rituxan) zisetshenziswa ngokuhambisana ne-relapsed / refractory chronic lymphocytic leukemia (CLL), okuholela esilinganisweni esiphezulu sesifo esincane esingatholakali se-residual (MRD), esifana ...